Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Phase 1b/2 trial results of intravitreal sepofarsen RNAtherapy in Leber congenital amaurosis 10 (LCA10) Presenter: …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Phase 1b/2 trial results of intravitreal sepofarsen RNAtherapy in Leber congenital amaurosis 10 (LCA10) Presenter: …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … amaurosis 10 (LCA10) and the investigational RNAtherapy for LCA10, sepofarsen experience to date. The call …
… in Q1 2022 Sepofarsen is a potential first-in-class RNAtherapy for the treatment of LCA10, a rare inherited retinal … to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that …
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan.
… ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs In … to changing lives through the creation of transformative RNA therapies, today provided an update on its ophthalmology … s epofarsen Sepofarsen (QR-110) is an investigational RNAtherapy designed to restore vision in Leber congenital …